EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioNexus Gene Lab's enterprise value is $4.45 Mil.
BioNexus Gene Lab's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.49 Mil. Therefore, BioNexus Gene Lab's EV-to-EBITDA for today is -1.79.
The historical rank and industry rank for BioNexus Gene Lab's EV-to-EBITDA or its related term are showing as below:
BGLC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -932.25 Med: 201.23 Max: 1314.47
Current: -1.83
During the past 6 years, the highest EV-to-EBITDA of BioNexus Gene Lab was 1314.47. The lowest was -932.25. And the median was 201.23.
BGLC's EV-to-EBITDA is ranked worse than 100% of 1287
companies
in the Chemicals industry
Industry Median: 14.13
vs BGLC: -1.83
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
BioNexus Gene Lab EV-to-EBITDA Historical Data
The historical data trend for BioNexus Gene Lab's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioNexus Gene Lab's EV-to-EBITDA
For the Specialty Chemicals subindustry, BioNexus Gene Lab's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab's EV-to-EBITDA Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's EV-to-EBITDA falls into.
BioNexus Gene Lab's current Enterprise Value is $4.45 Mil.
BioNexus Gene Lab's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
BioNexus Gene Lab's PE Ratio for today is calculated as:
BioNexus Gene Lab's share price for today is $0.5851.
BioNexus Gene Lab's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.176.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of BioNexus Gene Lab's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNexus Gene Lab (BioNexus Gene Lab) Business Description
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your 